Valneva Achieves Positive Phase 1 Results for Zika Vaccine VLA1601
Immune response successfully improved with second generation vaccine candidate
Valneva SE, a specialty vaccine company, announced encouraging results from its Phase 1 clinical trial of VLA1601, an advanced adjuvanted inactivated vaccine candidate developed to fight the Zika virus.
Details of the Phase 1 Trial
The trial, designated VLA1601-102, involved around 150 participants aged 18 to 49. Conducted in the United States, it included multiple doses of VLA1601 administered four weeks apart. The study scrutinized low, medium, and high doses of VLA1601, principally made with aluminum adjuvants. The low dose was additionally tested with alternative adjuvants from Dynavax Technologies and the Access to Advanced Health Institute.
Safety and Immunogenicity Findings
Results collected up to Day 57 indicated that VLA1601 was safe and well-tolerated across the various treatment groups, with no safety issues formally recognized. An independent monitoring board corroborated these findings, validating the safety profile of the vaccine.
The immune response generated by VLA1601 displayed significant efficacy. Notably, the double-adjuvanted arms outperformed the single-adjuvant group, indicating a clear enhancement in the immune response, with higher antibody titers observed on Days 43 and 57.
Comparison with First-Generation Vaccine
The newly tested VLA1601 demonstrated notably better results compared to its predecessor vaccine, achieving seroconversion rates exceeding 93% as opposed to 86% for the first-generation variant, alongside remarkable increases in antibody response levels.
Manufacturing Platform and Future Steps
Developed on the same manufacturing platform as Valneva's existing Japanese encephalitis vaccine, IXIARO, VLA1601 represents a paradigm shift towards a robust response against ZIKV. Valneva’s ongoing commitment to vaccine development includes their well-regarded COVID-19 vaccine.
Comments from Leadership
Juan Carlos Jaramillo M.D., the Chief Medical Officer, expressed optimism regarding the trial's outcome, emphasizing the urgency of addressing the challenges posed by Zika virus as climate conditions expand the habitats of mosquito vectors.
Challenges Ahead
Despite these promising results, Valneva recognizes the uncertainties involved in regulatory pathways and market prospects for Zika vaccines. Development of VLA1601 is contingent on securing substantial private and public funding.
Understanding the Zika Virus
The Zika virus, a mosquito-borne flavivirus, was identified in the late 1940s and has since caused outbreaks globally. The virus is associated with severe health issues, including congenital microcephaly and Guillain-Barré syndrome, highlighting the urgent need for effective vaccination strategies.
About Valneva SE
Valneva is committed to addressing infectious diseases through innovative vaccines. With a focus on unmet medical needs, the company leverages its extensive expertise to develop vaccines targeting various diseases, notably Zika, Lyme disease, and Shigella. Valneva's experience brings us closer to understanding and managing these health threats.
Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
VP, Global Communications and European Investor Relations
M +33 (0)6 4516 7099
communications@valneva.com
Joshua Drumm, Ph.D.
VP, Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
Frequently Asked Questions
What are the key findings from the Phase 1 trial of VLA1601?
The Phase 1 trial indicated that VLA1601 is safe, well-tolerated, and induced a strong immune response, particularly with the double-adjuvanted formulation.
How does VLA1601 compare to Valneva's first-generation Zika vaccine?
VLA1601 showed enhanced immune response metrics, including higher seroconversion rates and antibody titers compared to the first-generation vaccine.
What is the significance of the trial location?
The trial was conducted in the United States with diverse participants, ensuring a comprehensive examination of the vaccine's effectiveness.
What are the future steps for Valneva?
Valneva will evaluate potential development paths for VLA1601 based on funding opportunities, aiming to further advance the vaccine towards regulatory approval.
What is the Zika virus and its health implications?
The Zika virus can cause significant health issues, including birth defects like microcephaly and neurological complications, necessitating effective vaccination strategies.
